БЕТА-АДРЕНОБЛОКАТОРЫ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ: АКЦЕНТ НА НЕБИВОЛОЛ

1. Fields L.E, Burt V.L., Cutler J.A. The burden of adult hypertension in the United States, 1999 to 2000: a rising tide. Hypertension 44, 398-404(2004).

2. Hajjar I., Kotchen Т.А. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. J. Am. Med. Assoc. 290, 199-206 (2003).

3. Psaty B.M., Furberg C.D., Kuller L.H.et al. Association between blood pressure level and the risk of myocardial infarction, stroke and total mortality: the cardiovascular health study. Arch. Intern. Med. 161, 1183-1192(2001).

4. Coresh J., Wei G.L., McQuillan G. et al. Prevalence of high blood pressure and elevated serum creatinine level in the USA: findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch. Intern. Med. 161, 1207-1216 (2001).

5. Wilson P.W. Established risk factors and coronary artery disease: the Framingham Study. Am. J. Hypertens. 7(7 Pt 2), S7-S12 (1994).

6. Lopez-Sendon J., Swedberg K., McMurray J. et al. Expert consensus document on p-adrenergic receptor blockers. Eur. Heart J. 25, 1341-1362(2004).

7. Ubel P.A., Jepson C., Asch D.A. Misperceptions about p-blockers and diuretics: a national survey of primary care physicians. J. Gen. Intern. Med. 18, 977-983 (2003).

8. Ко D.T., Hebert P.R., Coffey C.S. et al. p-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. J. Am. Med. Assoc. 288, 351-357 (2002).

9. Jacob S., Rett K., Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of p-blocking agents? Am. J. Hypertens. 11, 1258-1265 (1998).

10. Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? Lancet 364, 1684-1689 (2004).

11. Lindholm L.H., Carlberg B., Samuelsson O. Should p blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366, 1545-1553 (2005).

12. Weber M. The role of the new p-blockers in treating cardiovascular disease. Am. J. Hypertens. 18, 169S-176S (2005).

13. Gielen W., Cleophas T.J., Agrawal R. Nebivolol. A review of its clinical and pharmacological characteristics. Int. J. Clin. Pharmacol. Ther. 44, 344-357 (2006).

14. Prichard BNC. Pharmacologic aspects of intrinsic sympathomimetic activity in p-blocking drugs. Am. J. Cardiol. 59, 13F-17F (1987).

15. McDevitt DG. Pharmacologic aspects of cardioselectivity in a -blocking drug. Am. J. Cardiol. 59, 10F-12F (1987).

16. Bristow M.R. p-adrenergic receptor blockade in chronic heart failure. Circulation 101, 558-569 (2000).

17. Bristow M. Characterization of p β-adrenergic receptor selectivity of nebivolol and various p-blockers in human myocardium. Am. J. Hypertens. 18(Pt 2), 51A-52A (2005).

18. Moen M.D., Wagstaff A.J. Nebivolol. A review of its use in the management of hypertension and chronic heart failure. Drugs 66, 1389-1409 (2006).

19. Ignarro L.J. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation p-blocker. Blood Pressure 13(S1), 3-17 (2004).

20. Bowman A.J., Chen CPL-H., Ford G.A. Nitric oxide mediated venodilator effects of nebivolol. Br. J. Clin. Pharmac. 38, 199-204 (1994).

21. Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther. 274, 1067-1071 (1995).

22. Tzemos N., Lim P.O., MacDonald T.M.Nebivololreversesendothelial dysfunction in essential hypertension. Circulation 104, 511-514 (2001).

23. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey (1988-1991). Hypertension 25, 305-313(1995).

24. Campia U., Choucair W.K., Bryant M.B. et al. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. J.Am. Coll. Cardiol. 40, 754-760 (2002).

25. McEniery C.M., Schmitt M., Qasem A. et al. Nebivolol increases arterial distensibility in vivo. Hypertension 44, 305-310 (2004).* Demonstrates the ability of nebivolol to attenuate large arterial stiffness that often accompanies hypertension, particularly in elderly patients.

26. Mason R.P., Kalinowski L., Jacob R.F. et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 112, 3795-3801 (2005). Demonstrates the effects of nebivolol on nitric oxide (NO) in a patient group that is thought to be deficient in NO compared with aged-matched Caucasians.

27. Pasini A.F., Garbin U., Nava M.C. et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 23, 589-596 (2005). Provides insight into the antioxidant effects of nebivolol.

28. Falciani M., Rinaldi B., D'Agostino В. et al. Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 38, 922-929 (2001).

29. Brehm B.R., Wolf S.C., Bertsch D. et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res. 49, 430-439 (2001).

30. Pessina A.C. Metabolic effects and safety profile of nebivolol. J. Cardiovasc. Pharmacol. 38(Suppl. 3), 33-35 (2001).

31. Poirier L., Cffiroux J., Nadeau A. et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J. Hypertens. 19, 1429-1435 (2001).

32. Kuroedov A., Cosentino F., Luscher T.F. Pharmacological mechanisms of clinically favorable properties of a selective 1-adrenoceptor antagonist, nebivolol. Cardiovasc. Drug Rev. 22, 155-168(2004).

33. Celik T., Iyisoy A., Kursaklioglu H. et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens. 24, 591-596 (2006).

34. Uhlir O., Dvorak I., Gregor P. et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J. Card. Fail. 3, 271-276 (1997).

35. Dal Negro R.W., Tognella S., Micheletto C. Pharmacokinetics of the effect of nebivolol 5mg on airway patency in patients with mild to moderate bronchial asthma and arterial hypertension: a randomized, placebo-controlled study. Clin. Drug Invest. 22, 197-204 (2002).

36. Dal Negro R.W., Tognella S., Pomari C. Once-daily nebivolol 5mg doses does not reduce airway patency in patients with chronic obstructive pulmonary disease and arterial hypertension: a placebo-controlled crossover study. Clin. Drug Invest. 22, 361-367 (2002).

37. Kamali F., Howes A., Thomas S.H. et al. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br. J. Clin. Pharmacol. 43, 201-204 (1997).

38. Shaw A.A., Ziemniak J., Liu S. et al. Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers [abstract]. Clin. Pharmacol. Ther. 77, 77 (2005).

39. Cheymol G., Woestenborghs R., Snoeck E. et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur. J. Clin. Pharmacol. 51, 493-498 (1997).

40. Gu Z., Robinson R.A., Cai L. et al. Metabolism study of 14C-nebivolol in humans with different CYP2D6 genotypes [abstract]. AAPS Pharm Sci 5, T3362 (2003).

41. Janssens W.J., Snoeck E. Pharmacology and pharmacokinetics of nebivolol. Symposium on endothelium in hypertension. New Therapeutic Trends. 1, 10-13 (1997).

42. Lawrence Т.Е., Liu S., Fisher J.W. et al. No interaction between nebivolol and digoxin in healthy volunteers [abstract]. Clin. Pharmacol. Ther. 77, 76 (2005).

43. Lawrence Т.Е., Chien C., Tu H.C. et al. Single-dose pharmacokinetics and anticoagulant activity of warfarin is unaffected by nebivolol in healthy volunteers [abstract]. Clin. Pharmacol. Ther. 77, 39 (2005).

44. Lawrence Т.Е., Chien C., Tu H.C. et al. No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 status [abstract]. Clin. Pharmacol. Ther. 77, 82 (2005).

45. Morton T.L.,Tu Н.С., Liu S.etal. Lack of pharmacokinetic interaction between nebivolol and spironolactone [abstract]. Clin. Pharmacol. Ther. 77(2), 46 (2005).

46. Morton T.L., Liu S,. Phillips J.L. et al. Pharmacokinetics of nebivolol and ramipril are not affected by co-administration [abstract]. Clin. Pharmacol. Ther. 77, 77 (2005).

47. Morton T.L., Liu S., Phillips J.L. et al. No pharmacokinetic interaction between nebivolol and furosemide in healthy subjects [abstract]. Clin. Pharmacol. Ther. 77, 79 (2005).

48. Shaw A.A., Liu S., Zachwieja L.F. et al. Effect of cliromc administration of fluoxetine on the pharmacokinetics of nebivolol [abstract]. Clin. Pharmacol. Ther. 77, 38 (2005).

49. Van Bortel LMAB, Breed JGS, Joosten J, et al. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J. Cardiovasc. Pharmacol. 21, 856-862 (1993).

50. Van Nueten L., Dupont A.G., Vertommen C., et al. A dose-response trial of nebivolol in essential hypertension. J. Hum. Hypertens. 11, 139-144(1997).

51. Weiss P.J., Weber M.A., Carr A.A., et al. A randomized, double-blind placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel p-blocker, in patients with mild to moderate hypertension. J. Clin. Hypertens. 9, 667-676 (2007). Instrumental in the US FDA decision to approve nebivolol for use in hypertension.

52. Saunders E., Smith W.B., DeSalvo K.B., et al. The efficacy and tolerability of nebivolol in hypertensive African American patients. J. Clin. Hypertens. 9,866-875 (2007). Instrumental in the FDA decision to approve nebivolol for use in hypertension as well as demonstrating nebivolol's effectiveness in African-American patients.

53. Van Nueten L., Taylor F.R., Robertson J.I.S. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J. Hum. Hypertens. 12, 135-140 (1998).

54. Czuriga I., Riecansky I., Bodnar J. et al. Comparison of the new cardioselective p -blocker nebivolol with bisoprolol in hypertension: the nebivolol, bisoprolol multicenter study (NEBIS). Cardiovasc. Drugs Ther. 17, 257-263 (2003).

55. Uhlir O., Fejfusa M., Havranek К. et al. Nebivolol versus metoprolol in the treatment of hypertension. Drug Invest. 3(S1), 107-110 (1991).

56. Brixius K., Middeke M., Lichtenthal A. et al. Nitric oxide, erectile dysfunction and p-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin. Exp. Pharm. Phys. 34, 327-331 (2007).

57. Van Nueten L., Lacourciere Y., Vyssoulis G. et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized comparative trial. Am. J. Ther. 5, 237-243 (1998).

58. Mazza A., Gil-Extremera B., Maldonato A. et al. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. 11, 182-188 (2002).

59. Van Nueten L., Schelling A., Vertommen C. et al. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J. Hum. Hypertens. 11, 813-819 (1997).

60. Rosei E.A., Rizzoni D., Comini S. et al. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press. 12(S1), 30-35 (2003).

61. Van Bortel L.M., Bulpitt C.J., Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am. J. Hypertens. 18, 1060-1066 (2005).

62. Lacourciere Y., Lefebvre J., Poirier L. et al. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial-design trial. Am. J. Hypertens. 7, 137-145 (1994).